Modern targeted therapies have revolutionized the treatment of blood cancers by interfering with the molecular drivers of disease. Dasanat contains dasatinib, a second‑generation tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that express the Philadelphia chromosome. By binding to the BCR‑ABL fusion protein and inhibiting a range of other kinases including SRC family kinases, dasatinib disrupts abnormal signaling pathways that promote cancer cell growth. Dasanat may be used in newly diagnosed chronic phase CML or in patients who are intolerant or resistant to imatinib or other first‑line therapies. When taken as prescribed, it can induce cytogenetic and molecular responses, delay disease progression and improve survival.
Dasanat tablets are available in various strengths; dosing is individualized based on disease phase, treatment history, age and comorbidities. Typical starting doses range from 100 mg once daily for chronic phase CML to 140 mg once daily for advanced phases or Ph+ ALL. Take the tablet whole with or without food at the same time each day, and do not crush or chew it. Grapefruit products should be avoided, as they may increase drug levels. Because many drugs interact with dasatinib, including strong CYP3A4 inhibitors/inducers, antacids and certain anticoagulants, inform your healthcare provider about all medications and supplements you use.
Common side effects include nausea, diarrhea, abdominal pain, headache, fatigue, muscle cramps, rash, and fluid retention (edema or pleural effusion). Dasatinib may also cause myelosuppression, leading to low white blood cell, red blood cell, or platelet counts; regular blood tests are essential to monitor for these effects. Serious adverse events such as pulmonary arterial hypertension, QT interval prolongation, bleeding, infections or liver toxicity can occur. Seek immediate medical attention if you experience chest pain, shortness of breath, unexplained bruising or bleeding.
Dasanat is not appropriate for pregnant or breastfeeding women because it can harm a developing fetus. Use effective contraception during treatment and for a period after discontinuation. Patients with heart disease, bleeding disorders or severe hepatic impairment should use caution. Only take this medication under the supervision of an oncologist experienced in managing CML or Ph+ ALL. With careful monitoring, Dasanat can be a highly effective component of targeted leukemia therapy.
Dasanat tablets are available in various strengths; dosing is individualized based on disease phase, treatment history, age and comorbidities. Typical starting doses range from 100 mg once daily for chronic phase CML to 140 mg once daily for advanced phases or Ph+ ALL. Take the tablet whole with or without food at the same time each day, and do not crush or chew it. Grapefruit products should be avoided, as they may increase drug levels. Because many drugs interact with dasatinib, including strong CYP3A4 inhibitors/inducers, antacids and certain anticoagulants, inform your healthcare provider about all medications and supplements you use.
Common side effects include nausea, diarrhea, abdominal pain, headache, fatigue, muscle cramps, rash, and fluid retention (edema or pleural effusion). Dasatinib may also cause myelosuppression, leading to low white blood cell, red blood cell, or platelet counts; regular blood tests are essential to monitor for these effects. Serious adverse events such as pulmonary arterial hypertension, QT interval prolongation, bleeding, infections or liver toxicity can occur. Seek immediate medical attention if you experience chest pain, shortness of breath, unexplained bruising or bleeding.
Dasanat is not appropriate for pregnant or breastfeeding women because it can harm a developing fetus. Use effective contraception during treatment and for a period after discontinuation. Patients with heart disease, bleeding disorders or severe hepatic impairment should use caution. Only take this medication under the supervision of an oncologist experienced in managing CML or Ph+ ALL. With careful monitoring, Dasanat can be a highly effective component of targeted leukemia therapy.
0